Kura Oncology (NASDAQ:KURA) CEO Troy Edward Wilson Acquires 100,000 Shares

Kura Oncology, Inc. (NASDAQ:KURA) CEO Troy Edward Wilson bought 100,000 shares of the business’s stock in a transaction on Monday, August 24th. The stock was acquired at an average cost of $12.39 per share, for a total transaction of $1,239,000.00. Following the completion of the transaction, the chief executive officer owned 479,194 shares in the company, valued at $5,937,213.66. This represents a 26.37% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Troy Edward Wilson also recently made the following trade(s):

• On Monday, August 17th, Troy Edward Wilson purchased 100,000 shares of Kura Oncology stock. The shares were bought at an average price of $11.12 per share, for a total transaction of $1,112,000.00.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA opened at $12.40 on Tuesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The business has a fifty day moving average of $10.59 and a 200-day moving average of $9.50. The firm has a market cap of $1.10 billion, a PE ratio of -3.68 and a beta of 0.38. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $12.90.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.11. The company had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. On average, equities research analysts predict that Kura Oncology, Inc. will post -3.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on KURA. Morgan Stanley set a $24.00 price objective on Kura Oncology in a research report on Monday. Citizens Jmp reaffirmed a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a research report on Monday. Wedbush boosted their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. Sanford C. Bernstein set a $24.00 target price on shares of Kura Oncology in a report on Monday, June 15th. Finally, Wells Fargo & Company set a $24.00 target price on Kura Oncology in a report on Thursday, June 4th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $25.40.

Institutional Trading of Kura Oncology

Institutional investors have recently modified their holdings of the company. IFP Advisors Inc lifted its stake in Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after purchasing an additional 1,284 shares during the last quarter. Allworth Financial LP increased its position in Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after acquiring an additional 1,553 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Kura Oncology by 49.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock worth $60,000 after purchasing an additional 1,888 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after acquiring an additional 9,958 shares during the period. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Kura Oncology in the second quarter worth $80,000.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.